April 2020: Partner Spotlight - Sanofi

April 2020: Partner Spotlight - Sanofi

Given the COVID-19 pandemic and the concerns some people living with diabetes may have about their risks and ability to access their medications, Sanofi, as one of the leading insulin manufacturers, wants to reassure people living with diabetes that they remain committed to offering innovative solutions to provide affordable access to medicines.

Sanofi fully understands that the price and affordability of their products is important for patients. That is why in 2017 they announced their progressive, industry-leading pricing principles, which includes a pledge to keep annual list price increases at or below the CMS-calculated National Health Expenditure (NHE) growth rate, to help stakeholders understand their pricing decisions and to advance a more informed discussion of issues related to the pricing of medicines. You can read more about their Pricing Policy in their 2020 Pricing Report here.

Further, Sanofi has adopted a variety of approaches to work within the current system to improve access and affordability of insulin for patients. They have developed some of the most forward-leaning programs to help patients afford Sanofi's insulin products. For example:

  • Insulins Valyou Savings Program: All uninsured patients, regardless of income level, can access one or multiple Sanofi insulins* for a fixed price of $99 per month for up to 10 boxes of pens and/or 10mL vials. In 2019, this program was used 52,220 times resulting in $17.6 million of patient savings.
  • Co-pay Assistance Programs: All commercially insured patients, regardless of income level, can participate in this program which limits out-of-pocket expenses for a majority of patients to $0 or $10.
  • Sanofi Patient Connection: Qualified low- and middle-income patients can receive free medications through the patient assistance component of this program. In 2019, 56,000 patients received free insulin through Sanofi patient assistance programs.

“We are proud of the diverse programs we have developed, based on input from patients, to improve affordability of Sanofi diabetes medicines. We encourage anyone who is struggling to afford a prescribed Sanofi diabetes medicine, especially those who have been impacted by the COVID-19 pandemic, to call (855) 984-6302. We have a team of trained professionals available to help eligible patients access the medicines and resources they need,”said Adam Gluck, Head of U.S. & Sanofi Genzyme Corporate Affairs at Sanofi.

Click here to see additional information on Sanofi’s diabetes savings programs.

* The Insulins Valyou Savings Program does not include Sanofi's combination insulin product.

 

Sanofi is a 2020 National Strategic Partner of DiabetesSisters. DiabetesSisters shares information they provide that is useful to our community; however, the relationship does not influence the decisions or opinions of DiabetesSisters, its governing board or staff.